Abstract
Cardiovascular Diseases (CVD) remain the leading cause of mortality and morbidity worldwide. To date, significant progress has been made in developing stimuli-responsive nanosystems that can intrinsically interact with pathological microenvironment to achieve site-specific delivery along with on-demand drug release for precise CVD treatment. Herein, this review summarizes recent advances on smart nanosystems in response to a wide range of biological cues, including pH, enzymes, ROS, shear force, ATP, etc., which can boost drug delivery performance or monitor disease progression in a non-invasive manner. The designs, compositions and main outcomes of the single and multi-responsive nanosystems for drug delivery and/or detection purposes are provided and discussed.
Keywords: Biologically responsive, nanosystems, nanoparticle, drug delivery, stimuli-triggered drug release, cardiovascular diseases.
Graphical Abstract
Current Drug Delivery
Title:Biologically Responsive Nanosystems Targeting Cardiovascular Diseases
Volume: 18 Issue: 7
Author(s): Zhiling Song, Kechen Song, Yi Xiao, Hui Guo, Yizhun Zhu*Xiaolin Wang*
Affiliation:
- State Key Laboratory of Quality Research in Chinese Medicine and School of Pharmacy, Macau University of Science and Technology, Taipa, Macao,China
- State Key Laboratory of Quality Research in Chinese Medicine and School of Pharmacy, Macau University of Science and Technology, Taipa, Macao,China
Keywords: Biologically responsive, nanosystems, nanoparticle, drug delivery, stimuli-triggered drug release, cardiovascular diseases.
Abstract: Cardiovascular Diseases (CVD) remain the leading cause of mortality and morbidity worldwide. To date, significant progress has been made in developing stimuli-responsive nanosystems that can intrinsically interact with pathological microenvironment to achieve site-specific delivery along with on-demand drug release for precise CVD treatment. Herein, this review summarizes recent advances on smart nanosystems in response to a wide range of biological cues, including pH, enzymes, ROS, shear force, ATP, etc., which can boost drug delivery performance or monitor disease progression in a non-invasive manner. The designs, compositions and main outcomes of the single and multi-responsive nanosystems for drug delivery and/or detection purposes are provided and discussed.
Export Options
About this article
Cite this article as:
Song Zhiling , Song Kechen , Xiao Yi , Guo Hui , Zhu Yizhun *, Wang Xiaolin *, Biologically Responsive Nanosystems Targeting Cardiovascular Diseases, Current Drug Delivery 2021; 18 (7) . https://dx.doi.org/10.2174/1567201818666210127093743
DOI https://dx.doi.org/10.2174/1567201818666210127093743 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gender Differences in Cancer-associated Venous Thromboembolism
Current Medicinal Chemistry Allergen-Induced Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia
Current Medicinal Chemistry Farnesoid-X Receptor (FXR) as a Promising Pharmaceutical Target in Atherosclerosis
Current Medicinal Chemistry Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy
Current Drug Targets Fourth Generation of Synthetic Cannabinoid Receptor Agonists: A Review on the Latest Insights
Current Pharmaceutical Design Cellular and Physiological Effects of Soy Flavonoids
Mini-Reviews in Medicinal Chemistry Epidemiology and Risk Factors of Cerebral Ischemia and Ischemic Heart Diseases: Similarities and Differences
Current Cardiology Reviews Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Current Cardiology Reviews ACE Inhibition Prevents Diastolic Ca2+ Overload and Loss of Myofilament Ca2+ Sensitivity after Myocardial Infarction
Current Molecular Medicine Combinations of Renin-Angiotensin-Aldosterone System Antagonists:True Advantages?
Current Pharmaceutical Design Recent Advances in Health Promoting Effect of Dietary Polyphenols
Current Nutrition & Food Science Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies
Current Bioactive Compounds Resistance to Anti-VEGF Agents
Current Pharmaceutical Design Nocturnal Hypertension and Chronic Kidney Disease
Current Hypertension Reviews Present Insights on Cardiomyopathy in Diabetic Patients
Current Diabetes Reviews Drug-Induced Pulmonary Hypertension in Newborns: A Review.
Current Vascular Pharmacology Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Aldose Reductase, Oxidative Stress and Diabetic Cardiovascular Complications
Cardiovascular & Hematological Agents in Medicinal Chemistry